Patrice Bonfiglio notified Amarin Corporation plc on November 16, 2026 of her decision to resign as a director, effective immediately. The resignation is not the result of any disagreement with the Company on its operations, policies or practices.
AMRN · Amarin Corp Plcuk
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 52%
- Last earnings
- Oct 28, 2026
- Latest filing
- 10-Q · Oct 28
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Third-quarter 2026 net revenue was $39.6 million, down from $49.7 million a year earlier, and net income was $245,000. A colorectal cancer trial of the drug missed its primary progression-free survival endpoint but showed a 32% lower hazard of death in overall survival.
Amarin reported total revenue, net, of $39.6 million for the three months ended September 30, 2026, down $10.1 million, or 20%, from $49.7 million a year earlier. The decrease was due primarily to a $12.3 million decline in U.S. net product revenue. Gross margin on product sales fell to 37% from 43%, mainly due to a change in customer mix.
Amarin reported third-quarter 2026 net income of $0.2 million, against a net loss of $(7.7) million a year earlier. Total net revenue fell 20% to $39.6 million. Cash and short-term investments reached $323.4 million, and the company remains debt-free.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Oct 28, 2026TL;DR. Amarin returned to quarterly profitability, cut Q3 operating expenses 44%, generated positive operating cash flow, ended with $323.4 million of cash and investments and no debt, while global partner-network in-market demand rose 55% and U.S. IPE share held at 47%; it expects positive Q4 operating cash flow and about $330 million of cash. Revenue declined 20% amid U.S. generic-driven pricing pressure, partner purchasing may not match international demand growth, and EMT2 missed its primary endpoint despite a statistically significant overall-survival benefit.
- + Returned to quarterly profitability, reporting $245,000 of net income versus a $7.7 million loss new
- + Cut Q3 operating expenses 44% and expects further reductions in Q4 new
- + Improved year-to-date operating cash flow to $22 million from a $9 million outflow new
- + Maintained U.S. IPE market leadership with 47% share and expects broadly stable volumes new
- + EMT2 showed a statistically significant 32% lower hazard of death new
- − Partner purchasing may not grow in line with international in-market demand new
- − EMT2 failed to meet its primary progression-free-survival endpoint new
- − 2027 payer exclusivities remain unconfirmed amid normal product-exclusivity changes new
- − Q3 remained GAAP operating-loss-making despite returning to net profitability new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| commercially available | 22 | As of June 30, 2026 | — |
| in-market demand for VASCEPA/VAZKEPA | 59% | Q2 2026 | — |
| in-market demand in Europe | 69% | Q2 2026 | — |
| in-market volume in China | 90% | year-to-date | — |
| Net income (loss) for EPS1 - non-GAAP non-GAAP | -1M | Six months ended June 30, 2026 | — |
| share of the U.S. IPE market | 48% | Q2 2026 | — |
| VASCEPA branded prescriptions | 14% | Q2 2026 | — |
| VAZKEPA is commercialized in | 11 | As of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AMRN
this stock
Amarin Corp Plcuk
|
$473.40M | -19.3% | +39.2% | — | 1.3% |
|
LLY
ELI LILLY & Co
|
$1.27T | +25.7% | +44.7% | 43.9 | 0.8% |
|
JNJ
Johnson & Johnson
|
$643.09B | +29.1% | +6.0% | 40.6 | 0.7% |
|
ABBV
AbbVie Inc.
|
$501.19B | +24.1% | +8.6% | 48.8 | 0.9% |
|
MRK
Merck & Co., Inc.
|
$327.41B | +26.2% | +1.3% | 136.9 | 1.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 18, 2026
- This year
- 15
Patrice Bonfiglio notified Amarin Corporation plc on November 16, 2026 of her decision to resign as a director, effective immediately. The resignation is not the result of any disagreement with the Company on its operations, policies or practices.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AMRN | -3.5% | -2.9% | -21.6% | -7.0% | -19.3% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +1.9% | +3.4% | -16.0% | -1.8% | -24.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.